Gierula John, Paton Maria F, Witte Klaus K
Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, UK.
Future Cardiol. 2021 Jul;17(4):609-618. doi: 10.2217/fca-2020-0117. Epub 2021 Feb 26.
Cardiovascular implantable electronic devices have revolutionized the management of heart failure with reduced ejection fraction. New device generations tend to be launched every few years, with incremental improvements in performance and safety and with an expectation that these will improve patient management and outcomes while remaining cost-effective. As a result, today's cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillator devices are quite different from the pioneering but often bulky devices of the late 20th century. This review discusses new and improved features developed to target specific needs in managing heart failure patients, some of which are especially pertinent to the current worldwide healthcare situation, with focus on the latest generation of CRTs with defibrillator (CRT-Ds) and implantable cardioverter defibrillators from Medtronic.
心血管植入式电子设备彻底改变了射血分数降低的心力衰竭的管理方式。新一代设备往往每隔几年推出一次,在性能和安全性方面有渐进式改进,并且期望这些改进能改善患者管理和预后,同时保持成本效益。因此,如今的心脏再同步治疗(CRT)设备和植入式心脏复律除颤器与20世纪末的开创性但通常体积庞大的设备有很大不同。本综述讨论了为满足心力衰竭患者管理中的特定需求而开发的新的和改进的功能,其中一些功能尤其与当前全球医疗状况相关,重点介绍了美敦力公司最新一代的带除颤器的CRT(CRT-D)和植入式心脏复律除颤器。